Table 5.

Comparison of celiac antibodies according to treatment modalities of psoriasis.

	Methotrexate use		p	Biologic agent use		p
	Present a n = 22	Absent b n = 43		Present c n = 19	Absent d n = 46
Antigliadin IgA, median (IQR:25–75)	2.7 (2.1–4.5)	2.4 (1.5–4.3)	0.81	2.4 (2.0–4.6)	2.4 (1.5–5.2)	0.73
Antigliadin IgG, median (IQR:25–75)	3.0 (2.0–5.7)	3.4 (2.1–5.2)	0.53	3.2 (2.1–5.2)	3.2 (2.2–5.5)	0.82
Anti-TTG IgA, median (IQR:25–75)	2.3 (1.2–4.6)	2.4 (1.0–4.2)	0.96	3.1 (1.2–4.1)	2.2 (1.0–4.5)	0.39
Anti-TTG IgG, median (IQR:25–75)	2.1 (1.3–3.5)	2.9 (1.0–5.1)	0.29	4.1 (1.0–5.6)	2.1 (1.2–4.2)	0.10

IQR; interquartile range, TTG; tissue transglutaminase.

^aIn this group, 15 patients received only methotrexate, and seven patients received combined topical treatment with methotrexate.

^bIn this group, 21 patients received only topical therapy, 19 patients received only biological therapy, and three patients received acitretin.

^cAll patients in this group were treated with an anti-TNFα or anti-IL17A agent alone.

^dIn this group, 15 patients received only methotrexate, and seven patients combined topical treatment with methotrexate, 21 patients only topical therapy, and three patients acitretin.